LONDON — European regulators on Friday said that an Alzheimer’s therapy from Eisai and Biogen should be rejected, again diverging from their U.S. counterparts on a medicine for a condition where treatments are desperately needed.
In a statement, the regulators said that the benefits of Leqembi did not outweigh the risks of potentially dangerous side effects.
The negative review was issued by a European Medicines Agency committee that evaluates new drugs. While the final decision rests with the European Commission, it almost always follows the EMA’s recommendations.
